Latest Japanese Market News

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.

New Hope Group delivered a robust quarterly performance with a 21.8% rise in underlying EBITDA and a 33% jump in saleable coal production for the first half of FY25, underpinned by operational efficiencies and strategic investments.